IQ Therapeutics Completes Dosing of Antibody Against Anthrax in Phase I Clinical Trial
Therapeutics has completed the dosing of antibody IQNLF in a Phase I clinical
trial. A total of 36 healthy volunteers participated in the randomized,
placebo controlled, double blind, single dose-escalating study, intended to
assess the safety, tolerability, pharmacokinetics and pharmacodynamics of
IQNLF. The dosing has been completed successfully and doses up to 7.5 mg/kg
have been administered, as per protocol.
Inhalation anthrax is a potentially deadly infectious disease with
limited treatment options, in particular for the advanced stage of infection
after the initial appearance of symptoms. IQNLF is a fully human antibody
developed by IQ Therapeutics, as part of a dual antibody treatment of
inhalation anthrax. IQNLF is formulated in combination with a second fully
human antibody (IQNPA) forming IQ-DAA. Pre-clinical experiments have
indicated high efficacy of IQ-DAA, even in advanced stage of disease.
Survival rates of 100% could be obtained in post-exposure treatment rabbit
studies, even when administered 48 hours post-exposure, well into the
symptomatic stage of the disease.
“The outcome of the clinical study will provide more insight in the
safety of IQNLF and how well the antibody is accepted by the human body at
levels that are projected to be efficacious” says Dr.
IQ Therapeutics. “It represents another important milestone in the
development of IQ-DAA, and the initial results reflect the value of IQ’s
Cloning the Human Response technology.”
IQNLF and IQNPA have been developed using the Cloning the Human
Response(TM) technology, a proprietary technology of IQ Therapeutics,
generating fully human antibodies from immunized donors. The technology
results in antibodies which have been matured and optimized by the human
immune system and are therefore most suitable for fighting infectious
diseases in humans.
Anthrax is an acute infectious disease caused by the spore-forming
bacterium Bacillus anthracis. Inhalation anthrax is often fatal if not
treated immediately with the proper medication, before symptoms have
appeared. IQ Therapeutics is focusing on treatment of patients who have
become symptomatic and could otherwise not be saved with antibiotics. IQ
developed IQ-DAA, the “Dual Antibody Approach”, using a combination of two
monoclonal antibodies neutralizing the lethal toxin produced by Bacillus
anthracis, by targeting the PA and LF components of the toxin.
About IQ Therapeutics
IQ Therapeutics is a human antibody technology company based in
Immunity(TM) against healthcare threats, in particular in biodefense,
infectious diseases and oncology. The company is applying its Cloning the
Human Response(TM) technology to generate and develop fully human antibodies
from immunized donors. These novel antibodies populate the pipeline of IQ
Therapeutics and are also generated to support the portfolios of third
parties. DSM is a strategic partner through a venturing investment and
supplying the manufacturing capacity for monoclonal antibodies.
For more information, please visit http://www.iqtherapeutics.nl
SOURCE IQ Therapeutics BV